Clinical outcome and safety profile of metastatic pancreatic cancer patients treated with more than six cycles of nab-paclitaxel plus gemcitabine.

MLA

D’Angelo, Alberto, et al. “Clinical Outcome and Safety Profile of Metastatic Pancreatic Cancer Patients Treated with More than Six Cycles of Nab-Paclitaxel plus Gemcitabine.” Journal of Chemotherapy (Florence, Italy), vol. 35, no. 8, Dec. 2023, pp. 753–59. EBSCOhost, https://doi.org/10.1080/1120009X.2023.2190712.

APA

D’Angelo, A., Catalano, M., Conca, R., Petrioli, R., Siminonato, F., Cappetta, A., Roviello, G., & Ramello, M. (2023). Clinical outcome and safety profile of metastatic pancreatic cancer patients treated with more than six cycles of nab-paclitaxel plus gemcitabine. Journal of Chemotherapy (Florence, Italy), 35(8), 753–759. https://doi.org/10.1080/1120009X.2023.2190712

Chicago

D’Angelo, Alberto, Martina Catalano, Raffaele Conca, Roberto Petrioli, Francesca Siminonato, Alessandro Cappetta, Giandomenico Roviello, and Monica Ramello. 2023. “Clinical Outcome and Safety Profile of Metastatic Pancreatic Cancer Patients Treated with More than Six Cycles of Nab-Paclitaxel plus Gemcitabine.” Journal of Chemotherapy (Florence, Italy) 35 (8): 753–59. doi:10.1080/1120009X.2023.2190712.